It wasn’t all that long ago that Johnson & Johnson was touting head-to-head results for its psoriasis drug Tremfya against Novartis’ blockbuster Cosentyx. But now, a different rival has topped Tremfya in a showdown of its own.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,